JPH0153275B2 - - Google Patents
Info
- Publication number
- JPH0153275B2 JPH0153275B2 JP55138848A JP13884880A JPH0153275B2 JP H0153275 B2 JPH0153275 B2 JP H0153275B2 JP 55138848 A JP55138848 A JP 55138848A JP 13884880 A JP13884880 A JP 13884880A JP H0153275 B2 JPH0153275 B2 JP H0153275B2
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- oxa
- spiro
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960002256 spironolactone Drugs 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- ZAJNGDIORYACQU-UHFFFAOYSA-N methyl n-octyl ketone Natural products CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- UBEDATQLZJIEQK-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-[(dimethylamino)methyl]-1-oxaspiro[4.4]nonan-2-one Chemical compound C1CCCC21OC(=O)C(CN(C)C)C2C1=CC=C(Cl)C=C1 UBEDATQLZJIEQK-UHFFFAOYSA-N 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- OEBFKVOYRDTUGY-UHFFFAOYSA-N n,n-dimethyl-1-(4-phenyl-1-oxaspiro[4.5]decan-3-yl)methanamine Chemical compound C=1C=CC=CC=1C1C(CN(C)C)COC21CCCCC2 OEBFKVOYRDTUGY-UHFFFAOYSA-N 0.000 claims description 3
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- ZQBJUBIMAQXWLF-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-phenyl-1-oxaspiro[4.4]nonan-2-one Chemical compound C1CCCC21OC(=O)C(CN(C)C)C2C1=CC=CC=C1 ZQBJUBIMAQXWLF-UHFFFAOYSA-N 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims 2
- PYRCLXMIPGYWHM-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-1-oxaspiro[4.4]nonan-3-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(Cl)C=CC=1C1C(CN(C)C)COC21CCCC2 PYRCLXMIPGYWHM-UHFFFAOYSA-N 0.000 claims 1
- BMDDUDHWZFQAGI-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-(4-methylphenyl)-1-oxaspiro[4.5]decan-2-one Chemical compound C1CCCCC21OC(=O)C(CN(C)C)C2C1=CC=C(C)C=C1 BMDDUDHWZFQAGI-UHFFFAOYSA-N 0.000 claims 1
- CUKIUVSGMCKFCJ-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-phenyl-1-oxaspiro[4.5]decan-2-one Chemical compound C1CCCCC21OC(=O)C(CN(C)C)C2C1=CC=CC=C1 CUKIUVSGMCKFCJ-UHFFFAOYSA-N 0.000 claims 1
- 150000002596 lactones Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 230000009471 action Effects 0.000 abstract description 9
- 239000000935 antidepressant agent Substances 0.000 abstract description 3
- 229940005513 antidepressants Drugs 0.000 abstract description 3
- 150000001277 beta hydroxy acids Chemical class 0.000 abstract description 3
- 239000003176 neuroleptic agent Substances 0.000 abstract description 3
- 238000006683 Mannich reaction Methods 0.000 abstract description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- 230000000701 neuroleptic effect Effects 0.000 abstract description 2
- 230000008707 rearrangement Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003413 spiro compounds Chemical class 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 22
- 238000002844 melting Methods 0.000 description 21
- 230000008018 melting Effects 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960004801 imipramine Drugs 0.000 description 8
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 230000000891 anti-reserpine Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VYDIMQRLNMMJBW-UHFFFAOYSA-N cyclopentyl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCCC1 VYDIMQRLNMMJBW-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960000964 phenelzine Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 2
- SKRPUQQCFLUVLJ-UHFFFAOYSA-N 3-cyclopentyl-3-hydroxy-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(O)(CC(=O)O)C1CCCC1 SKRPUQQCFLUVLJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- KPJPHPFMCOKUMW-UHFFFAOYSA-N iodomethane Chemical compound I[CH2] KPJPHPFMCOKUMW-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- DJHRXBYWKVQDJY-UHFFFAOYSA-N spiro[4.5]decan-3-one Chemical compound C1C(=O)CCC21CCCCC2 DJHRXBYWKVQDJY-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OAUNRWNNNLUFEF-UHFFFAOYSA-N (4-chlorophenyl)-cyclopentylmethanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCCC1 OAUNRWNNNLUFEF-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- XWFDNJOSAQOKSJ-UHFFFAOYSA-N 3-cyclohexyl-3-hydroxy-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(O)(CC(=O)O)C1CCCCC1 XWFDNJOSAQOKSJ-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- VMWZRHGIAVCFNS-UHFFFAOYSA-J aluminum;lithium;tetrahydroxide Chemical compound [Li+].[OH-].[OH-].[OH-].[OH-].[Al+3] VMWZRHGIAVCFNS-UHFFFAOYSA-J 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003270 anti-cataleptic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NFZZBMGYMUGQBI-UHFFFAOYSA-N cyclohexyl-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1CCCCC1 NFZZBMGYMUGQBI-UHFFFAOYSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002897 effect on convulsion Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- IATJWQHWZUYXGC-UHFFFAOYSA-N nonane;hydrochloride Chemical compound Cl.CCCCCCCCC IATJWQHWZUYXGC-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ã¹ãã©ã³ååç©ã«é¢ãããã®ã§ããã
ç¹ã«æ¬çºæã¯ãïŒâã¢ãªãŒã«âïŒâã¢ããã¢ã«ã
ã«âïŒâãªããµâã¹ããã¢ã«ã«ã³é¡ãšïŒâã¢ãªãŒ
ã«âïŒâã¢ããã¢ã«ãã«âïŒâãªããµâã¹ããã¢
ã«ã«ã³âïŒâãªã³é¡ãšããããã®è£œæ³ãšãããã
ã®æ²»ççå¿çšã«é¢ãããã®ã§ããã
ç¹ã«æ¬çºæã¯ãïŒâã¢ãªãŒã«âïŒâã¢ããã¢ã«ã
ã«âïŒâãªããµâã¹ããã¢ã«ã«ã³é¡ãšïŒâã¢ãªãŒ
ã«âïŒâã¢ããã¢ã«ãã«âïŒâãªããµâã¹ããã¢
ã«ã«ã³âïŒâãªã³é¡ãšããããã®è£œæ³ãšãããã
ã®æ²»ççå¿çšã«é¢ãããã®ã§ããã
æ¬çºæã«ããã¹ãã©ã³èªå°äœã¯æ¬¡ã®äžè¬åŒ
ïŒïŒãæã€ã
ïŒïŒãæã€ã
ãã®åŒã§ãã¯æ°ŽçŽ åååã¯ããã²ã³ååãæ
ãã¯ã¢ã«ãã«åºåã¯ã¢ã«ã³ãã·åºã§ããïŒR1ãš
R2ã¯åäžåã¯ç°ãªããã®ã§ãã€ãŠãããããæ°Ž
çŽ åååã¯ã¢ã«ãã«åºãè¡šãããæãã¯R1ãšR2
ãäžã€ã«ãªã€ãŠå«çªçŽ è€çŽ ç°ã圢æãïŒïŒ¡ã¯
CH2åºåã¯COåºãè¡šããïŒïœã¯ïŒåã¯ïŒã§ã
ãã
ãã¯ã¢ã«ãã«åºåã¯ã¢ã«ã³ãã·åºã§ããïŒR1ãš
R2ã¯åäžåã¯ç°ãªããã®ã§ãã€ãŠãããããæ°Ž
çŽ åååã¯ã¢ã«ãã«åºãè¡šãããæãã¯R1ãšR2
ãäžã€ã«ãªã€ãŠå«çªçŽ è€çŽ ç°ã圢æãïŒïŒ¡ã¯
CH2åºåã¯COåºãè¡šããïŒïœã¯ïŒåã¯ïŒã§ã
ãã
R1ãšR2ããR1ãšR2ãçµåããŠçªçŽ ååãšå
±
ã«ãå«çªçŽ è€çŽ ç°ã圢æãããšãã¯ã該è€çŽ ç°ã¯
奜é©ã«ã¯ïŒå¡åã¯ïŒå¡ããæããäŸãã°ãããªã«
åºããããªãžãã«åºããããªãžãã«åºåã¯ããã
ã«é¡äŒŒããåºã§ããã
ã«ãå«çªçŽ è€çŽ ç°ã圢æãããšãã¯ã該è€çŽ ç°ã¯
奜é©ã«ã¯ïŒå¡åã¯ïŒå¡ããæããäŸãã°ãããªã«
åºããããªãžãã«åºããããªãžãã«åºåã¯ããã
ã«é¡äŒŒããåºã§ããã
æ¬çºæã¯åããšïœãäžè¬åŒãšåãæå³ãæ
ã€ãšãäžè¬åŒ ãæã€Î²âããããã·é žãåºçºç©è³ªãšããæ¿ç¡«é ž
ã®åŠãåŒ·é žãäœçšããã次ãã§å æ°Žå解ãããŠã
äžè¬åŒã®ååç©ã補é ããæ¹æ³ãç®çãšããã
ã®ã§ããããã®åå¿ã¯ãBull.Soc.Chim.de
FranceïŒ1970ïŒp.3609ã«G.Tsatasåã³G.Cottakis
ã«ãã€ãŠèšèŒãããåçã«åŸãååå 転äœã«ãã
è¡ãããããã®ããã«ããŠããšïœãäžè¬åŒäž
ãšåãå®çŸ©ãæã€ãšãäžè¬åŒ ãæã€Î³âã¹ããã©ã¯ãã³ãåŸãããã
ã€ãšãäžè¬åŒ ãæã€Î²âããããã·é žãåºçºç©è³ªãšããæ¿ç¡«é ž
ã®åŠãåŒ·é žãäœçšããã次ãã§å æ°Žå解ãããŠã
äžè¬åŒã®ååç©ã補é ããæ¹æ³ãç®çãšããã
ã®ã§ããããã®åå¿ã¯ãBull.Soc.Chim.de
FranceïŒ1970ïŒp.3609ã«G.Tsatasåã³G.Cottakis
ã«ãã€ãŠèšèŒãããåçã«åŸãååå 転äœã«ãã
è¡ãããããã®ããã«ããŠããšïœãäžè¬åŒäž
ãšåãå®çŸ©ãæã€ãšãäžè¬åŒ ãæã€Î³âã¹ããã©ã¯ãã³ãåŸãããã
äžè¬åŒã®ã¹ããã©ã¯ãã³ã«çé
žã¡ãã«ãã°ã
ã·ãŠã ãäœçšããããšãäžè¬åŒ ãæã€çžåœããαâã«ã«ããã·âγâã¹ããã©ã¯
ãã³ãããããã®ååç©ããMannichåå¿ã«åŸ
ã€ãŠããã«ããªã³åã¯ãã©ãã«ã ã¢ã«ãããã®å
åšäžã«ãäžè¬åŒHNR1R2ã§è¡šããããèèªæã¢
ãã³ãšäœçšãããŠããCOã§ããäžè¬åŒã®
æ¬çºæã®ååç©ã«ååŠå€åãããã
ã·ãŠã ãäœçšããããšãäžè¬åŒ ãæã€çžåœããαâã«ã«ããã·âγâã¹ããã©ã¯
ãã³ãããããã®ååç©ããMannichåå¿ã«åŸ
ã€ãŠããã«ããªã³åã¯ãã©ãã«ã ã¢ã«ãããã®å
åšäžã«ãäžè¬åŒHNR1R2ã§è¡šããããèèªæã¢
ãã³ãšäœçšãããŠããCOã§ããäžè¬åŒã®
æ¬çºæã®ååç©ã«ååŠå€åãããã
åèšåŒ·é
žã¯ãå·¥æ¥ã§æ®éçšãããã匷é
žãäŸã
ã°æ¿ç¡«é žã奜é©ã«ã¯çºç ç¡«é žã®å ±åããæ¿ç¡«é žã
å¡©é žãïœâãã«ãšã³ã¹ã«ãã³é žãéé žãã«ã€ã¹é ž
çããéžã¶ããšãã§ããã
ã°æ¿ç¡«é žã奜é©ã«ã¯çºç ç¡«é žã®å ±åããæ¿ç¡«é žã
å¡©é žãïœâãã«ãšã³ã¹ã«ãã³é žãéé žãã«ã€ã¹é ž
çããéžã¶ããšãã§ããã
æ¬çºæã®ä»ã®æ¹æ³ã«ããã°ããCH2ã§ãã
äžè¬åŒã®ååç©ã¯ããCOã§ããäžè¬åŒ
ã®ååç©ãåºçºäœãšããæ°ŽçŽ åãªããŠã ã¢ã«ãã
ãŠã ã«ããéå éç°ããŠãžãªãŒã«ã圢æãããã
ãªãžã³äžã§å¡©åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®
äœçšã«ããååå è±æ°ŽãããŠç°åããããšã«ãã
奜é©ã«åŸãããã
äžè¬åŒã®ååç©ã¯ããCOã§ããäžè¬åŒ
ã®ååç©ãåºçºäœãšããæ°ŽçŽ åãªããŠã ã¢ã«ãã
ãŠã ã«ããéå éç°ããŠãžãªãŒã«ã圢æãããã
ãªãžã³äžã§å¡©åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®
äœçšã«ããååå è±æ°ŽãããŠç°åããããšã«ãã
奜é©ã«åŸãããã
äžè¬åŒã®æ¬çºæã®ã¹ãã©ã³èªå°äœã®è£œé ã«åº
çºååç©ãšããŠçšããããäžè¬åŒã®Î²âããã
ãã·é žã¯åšç¥ã®æ¹æ³ã§å®¹æã«ããããšãã§ããã
äŸãã°ãReformastkyåå¿ã«ããããã¢é ¢é žãš
ãã«ã®åŠãããã²ã³åãšã¹ãã«ãšäºéãšé©åœãªã·
ã¯ãã¢ã«ãã«ã¢ãªãŒã«ã±ãã³ãåå¿ããã次ãã§
åŸããããšã¹ãã«ãããåããã
çºååç©ãšããŠçšããããäžè¬åŒã®Î²âããã
ãã·é žã¯åšç¥ã®æ¹æ³ã§å®¹æã«ããããšãã§ããã
äŸãã°ãReformastkyåå¿ã«ããããã¢é ¢é žãš
ãã«ã®åŠãããã²ã³åãšã¹ãã«ãšäºéãšé©åœãªã·
ã¯ãã¢ã«ãã«ã¢ãªãŒã«ã±ãã³ãåå¿ããã次ãã§
åŸããããšã¹ãã«ãããåããã
æ¬çºæã¯åããäžè¬åŒã®ã¹ãã©ã³èªå°äœã®
å¡©ãç¹ã«å¡©åæ°ŽçŽ é žãç¡«é žããªã³é žãé ¢é žããã
ããªã³é žãã·ãŠãŠé žãä¹³é žãã¯ãšã³é žãé ç³é žã
åã¯ããã³é žã®åŠãéåžžã®é žãšã®åå¿ã«ããè¬åŠ
çã«å容ã§ããå¡©ã«åã¶ãã®ã§ãããåãããã®
å¡©ã¯ãæ¬çºæã®ã¹ãã©ã³ååç©ã«ããã²ã³åã¢ã«
ãã«ãäœçšãããŠãã€ããããšãã§ãããããã
ã®å¡©ã¯æ®éã®æ¹æ³ã§ãããªãã¡ã¢ã«ã³ãŒã«ãã±ã
ã³ãå¡©çŽ å溶åªåã¯ãšãŒãã«ã®åŠãé©åœã«éžã°ã
ã溶åªäžã§å€§äœååŠéè«çå²åã§æ¬çºæã®ã¹ãã©
ã³èªå°äœãšé©åœãªé žãšãåå¿ãããŠããããšãã§
ããã
å¡©ãç¹ã«å¡©åæ°ŽçŽ é žãç¡«é žããªã³é žãé ¢é žããã
ããªã³é žãã·ãŠãŠé žãä¹³é žãã¯ãšã³é žãé ç³é žã
åã¯ããã³é žã®åŠãéåžžã®é žãšã®åå¿ã«ããè¬åŠ
çã«å容ã§ããå¡©ã«åã¶ãã®ã§ãããåãããã®
å¡©ã¯ãæ¬çºæã®ã¹ãã©ã³ååç©ã«ããã²ã³åã¢ã«
ãã«ãäœçšãããŠãã€ããããšãã§ãããããã
ã®å¡©ã¯æ®éã®æ¹æ³ã§ãããªãã¡ã¢ã«ã³ãŒã«ãã±ã
ã³ãå¡©çŽ å溶åªåã¯ãšãŒãã«ã®åŠãé©åœã«éžã°ã
ã溶åªäžã§å€§äœååŠéè«çå²åã§æ¬çºæã®ã¹ãã©
ã³èªå°äœãšé©åœãªé žãšãåå¿ãããŠããããšãã§
ããã
åæ¬çºæã¯ãäžè¬åŒã®ã¹ãã©ã³èªå°äœåã³è¬
åŠçã«å容ããããã®å¡©ãå»è¬ã®æå¹æåãšããŠ
çšããããšãé瀺ãããã®ã§ãããäºå®ã«æŒã
ãŠãäžè¬åŒã®ã¹ãã©ã³ååç©ã«å°±ããŠè¡ããã
è¬çåã³æ¯æ§è©Šéšã¯ããããã®ç©è³ªãæ²»çã«çšã
ãã«è¶³ãèå³ããæ§è³ªãæã€ããšãæããã«ã
ãã
åŠçã«å容ããããã®å¡©ãå»è¬ã®æå¹æåãšããŠ
çšããããšãé瀺ãããã®ã§ãããäºå®ã«æŒã
ãŠãäžè¬åŒã®ã¹ãã©ã³ååç©ã«å°±ããŠè¡ããã
è¬çåã³æ¯æ§è©Šéšã¯ããããã®ç©è³ªãæ²»çã«çšã
ãã«è¶³ãèå³ããæ§è³ªãæã€ããšãæããã«ã
ãã
è©Šéšã¯ãæ¬çºæã«ããã¹ãã©ã³èªå°äœãã¢ã©ã
ã¢ãŽã ã«ããæ°Žæžæ¿æ¶²ã®åœ¢ã§ã©ããåã³ããŠã¹ã«
çšããäœé10Kgããã容ç©0.1mlãçµå£çã«æäž
ããŠè¡ãããã
ã¢ãŽã ã«ããæ°Žæžæ¿æ¶²ã®åœ¢ã§ã©ããåã³ããŠã¹ã«
çšããäœé10Kgããã容ç©0.1mlãçµå£çã«æäž
ããŠè¡ãããã
ããŠã¹ã«å°±ããŠè©Šéšãããçµå£æ¯æ§ã«å°±ããŠã
èŽæ»éDL50ã350ä¹è³400mgïŒKgã§ããããšã瀺
ãããã
èŽæ»éDL50ã350ä¹è³400mgïŒKgã§ããããšã瀺
ãããã
æ¬çºæã®ã¹ãã©ã³ååç©ã¯äžæ¢ç¥çµç³»ã«äœçšã
ãããã詳现ã«èšãã°ãïŒâãžã¡ãã«ã¢ããã¡ã
ã«âïŒâããšãã«âïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³ãç¹å®ã®å®äŸãšããŠä»¥äžã«è©³çŽ°ã«ç€ºã
ããããã«ãæ¬çºæã®ã¹ãã©ã³ååç©ã¯æã¬ã»ã«
ãã³äœçšãšé®çäœçšãåããããã¢ãã¬ããªã³
æ§ãããããªãã¿ãã³æ§ãããŒããã³æ§ãé®çæ§
ã®å¹æãäžããç¥çµè¬çã®é¢ã§ã¯ã€ããã©ãã³ã®
åŠãææãã€å€ãšäŒŒããã®ã§ããã
ãããã詳现ã«èšãã°ãïŒâãžã¡ãã«ã¢ããã¡ã
ã«âïŒâããšãã«âïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³ãç¹å®ã®å®äŸãšããŠä»¥äžã«è©³çŽ°ã«ç€ºã
ããããã«ãæ¬çºæã®ã¹ãã©ã³ååç©ã¯æã¬ã»ã«
ãã³äœçšãšé®çäœçšãåããããã¢ãã¬ããªã³
æ§ãããããªãã¿ãã³æ§ãããŒããã³æ§ãé®çæ§
ã®å¹æãäžããç¥çµè¬çã®é¢ã§ã¯ã€ããã©ãã³ã®
åŠãææãã€å€ãšäŒŒããã®ã§ããã
æã¬ã»ã«ãã³äœçšïŒ
ã¬ã»ã«ãã³ã®åŸã«æ¬çºæã®åèšçæç©ãæäžã
ããšã25mgïŒKgã®æäžéã§ãã¬ã»ã«ãã³ã«ããæ¢
ã«èµ·ã€ãŠããäœæž©äœäžåã³çŒçŒäžåã«éšåçã«æ®
æããããšã瀺ããåŸã€ãŠã¬ã»ã«ãã³ããåã«æ
äžããã25mgïŒKgã®ã€ããã©ãã³ã®äœçšã«äŒŒãäœ
çšã瀺ãããäœæž©äœäžã®é¢ã§ããçšåºŠã®æ®æäœçš
ã瀺ãããããã®æã¬ã»ã«ãã³äœçšã¯ã€ããã©ã
ã³ã®ããããå£ãã
ããšã25mgïŒKgã®æäžéã§ãã¬ã»ã«ãã³ã«ããæ¢
ã«èµ·ã€ãŠããäœæž©äœäžåã³çŒçŒäžåã«éšåçã«æ®
æããããšã瀺ããåŸã€ãŠã¬ã»ã«ãã³ããåã«æ
äžããã25mgïŒKgã®ã€ããã©ãã³ã®äœçšã«äŒŒãäœ
çšã瀺ãããäœæž©äœäžã®é¢ã§ããçšåºŠã®æ®æäœçš
ã瀺ãããããã®æã¬ã»ã«ãã³äœçšã¯ã€ããã©ã
ã³ã®ããããå£ãã
ããã¢ãã¬ããªã³æ§ãããããªãã¿ãã³æ§å¹æïŒ
ããŠã¹ã«å°±ããŠã¢ã³ããšã¿ãã³ã®æ¯æ§ã®çžä¹äœ
çšãç 究ããããæ¬çºæã®åèšçæç©ã¯25mgïŒKg
ã§è©²æ¯æ§ã®åŒ·ãçžä¹äœçšã瀺ãããããã«å¯Ÿãã€
ããã©ãã³ã¯äžæŽ»æ§ã§ããã
çšãç 究ããããæ¬çºæã®åèšçæç©ã¯25mgïŒKg
ã§è©²æ¯æ§ã®åŒ·ãçžä¹äœçšã瀺ãããããã«å¯Ÿãã€
ããã©ãã³ã¯äžæŽ»æ§ã§ããã
ããŠã¹ã«æŒãããšãã³ãã³ã®æ¯æ§ã®çžä¹äœçšã®
è©Šéšã§ã¯ãïŒmgïŒKgã®æ¬çºæã®åèšçæç©ãäžç°
ã®ææãã€å€ïŒã€ããã©ãã³åã³ã¢ãããªãããª
ã³ïŒãã掻æ§ã倧ããããšã瀺ããã
è©Šéšã§ã¯ãïŒmgïŒKgã®æ¬çºæã®åèšçæç©ãäžç°
ã®ææãã€å€ïŒã€ããã©ãã³åã³ã¢ãããªãããª
ã³ïŒãã掻æ§ã倧ããããšã瀺ããã
ããŒããã³æ§å¹æïŒ
ç¥çµåŒç·©å€ïŒããã¯ãããã©ãžã³ïŒã§ã©ããã«
èªçºãããã«ã¿ã¬ãã·ãŒã®è©Šéšã§ã¯ãæ¬çºæã®å
èšçæç©ã¯è¯å¥œãªæã«ã¿ã¬ãã·ãŒäœçšã瀺ãåæ
äžéïŒ50mgïŒKgïŒã®ã€ããã©ãã³ããé·ãæç¶æ
éã瀺ãããããããªãããã€ããã©ãã³ãšåã
ããããŠã¹ã«ïŒ¬âããŒãã«ãã€ãŠèªçºãããåžžå
ã«å¯ŸããŠã¯æ¬çºæã®åèšååã¯åœ±é¿ããªããä»
æ¹ãã¢ã³ããšã¿ãã³ãšããšãã«ãžã³ã¯ïŒ¬âããŒã
ãšåŒ·ãçžä¹äœçšã瀺ãããããšãã«ãžã³åç¬ã»ã©
ã§ã¯ãªãã
èªçºãããã«ã¿ã¬ãã·ãŒã®è©Šéšã§ã¯ãæ¬çºæã®å
èšçæç©ã¯è¯å¥œãªæã«ã¿ã¬ãã·ãŒäœçšã瀺ãåæ
äžéïŒ50mgïŒKgïŒã®ã€ããã©ãã³ããé·ãæç¶æ
éã瀺ãããããããªãããã€ããã©ãã³ãšåã
ããããŠã¹ã«ïŒ¬âããŒãã«ãã€ãŠèªçºãããåžžå
ã«å¯ŸããŠã¯æ¬çºæã®åèšååã¯åœ±é¿ããªããä»
æ¹ãã¢ã³ããšã¿ãã³ãšããšãã«ãžã³ã¯ïŒ¬âããŒã
ãšåŒ·ãçžä¹äœçšã瀺ãããããšãã«ãžã³åç¬ã»ã©
ã§ã¯ãªãã
é®çæ§å¹æïŒ
ãã³ããã«ãã¿ãŒã«ã»ãããªãŠã ã§ããŠã¹ã«èª
çºããã麻é ã¯æ¬çºæã®åèšçæç©ã®50mgïŒKgã®
æäžã®åŸé·ãæç¶ãããããã®äœçšã¯ã€ããã©ã
ã³ãŸãã¯ããšãã«ãžã³ã®äœçšã«ãŸããã
çºããã麻é ã¯æ¬çºæã®åèšçæç©ã®50mgïŒKgã®
æäžã®åŸé·ãæç¶ãããããã®äœçšã¯ã€ããã©ã
ã³ãŸãã¯ããšãã«ãžã³ã®äœçšã«ãŸããã
é®çæ§äœçšïŒ
äžç°ã®ææãã€å€ãšå察ã«ãæ¬çºæã®åèšçæ
ç©ã¯ããŠã¹ã«æŒããŠæ¥µå€§é»æã·ãšãã¯ãŸãã¯ã«ã«
ãžã¢ãŸãŒã«ã«ãã€ãŠèªçºãããçæ£ã«å¯Ÿãäºå®äž
äœçšããªãããšãå®éšã«ãã瀺ãããã
ç©ã¯ããŠã¹ã«æŒããŠæ¥µå€§é»æã·ãšãã¯ãŸãã¯ã«ã«
ãžã¢ãŸãŒã«ã«ãã€ãŠèªçºãããçæ£ã«å¯Ÿãäºå®äž
äœçšããªãããšãå®éšã«ãã瀺ãããã
é®çäœçšïŒ
âç±æ¿è©Šéšã«ããé®çäœçšãç 究ããããã®çµ
æ50mgïŒKgã®æ¬çºæã®åèšçæç©ã¯ã³ãã€ã³ã«
å¹æµããäžæ¢æ§éº»é å€ã®äœçšãæã€ããšã瀺ã
ããããããŸã§ã«èšèŒãããããã®ç²Ÿç¥ç¶æ äœ
çšæ§ç©è³ªããã®ãããªäœçšã¯æã€ãŠããªãã
æ50mgïŒKgã®æ¬çºæã®åèšçæç©ã¯ã³ãã€ã³ã«
å¹æµããäžæ¢æ§éº»é å€ã®äœçšãæã€ããšã瀺ã
ããããããŸã§ã«èšèŒãããããã®ç²Ÿç¥ç¶æ äœ
çšæ§ç©è³ªããã®ãããªäœçšã¯æã€ãŠããªãã
âããŠã¹ã«æŒããŠãããšãã«ãã³ãŸããã³ã®è
¹
è å 泚å°ã«ããèªçºãããè ¹éšã®èŠçãªå»¶ã³ã®
æ°ã®æžå°ã«å°±ããŠé®çäœçšãç 究ããããæ¬çº
æã®åèšçæç©ã®é®çäœçšã¯æšæºé®çå€ã§ãã
ã¢ã¹ããªã³ã«å¹æµããã¢ãããªãããªã³åã³ã¢
ã³ããšã¿ãã³ã«é®çäœçšã«å¹æµãããã®ã§ãã€
ãã
è å 泚å°ã«ããèªçºãããè ¹éšã®èŠçãªå»¶ã³ã®
æ°ã®æžå°ã«å°±ããŠé®çäœçšãç 究ããããæ¬çº
æã®åèšçæç©ã®é®çäœçšã¯æšæºé®çå€ã§ãã
ã¢ã¹ããªã³ã«å¹æµããã¢ãããªãããªã³åã³ã¢
ã³ããšã¿ãã³ã«é®çäœçšã«å¹æµãããã®ã§ãã€
ãã
åããæ¬çºæã®ååç©ã¯ãããŠã¹ã«å°±ããŠ25ä¹
è³50mgïŒKgã®æäžéã§èšŒæããããšããã§ã¯ãäž
æ¢åã³æ«æ¢¢ç¥çµæ§ã®ã³ãªã³æå¶æ§ãæã€ã
è³50mgïŒKgã®æäžéã§èšŒæããããšããã§ã¯ãäž
æ¢åã³æ«æ¢¢ç¥çµæ§ã®ã³ãªã³æå¶æ§ãæã€ã
ãã®å€ã«æ¬çºæã«ããã¹ãã©ã³ååç©ã¯ãã¢ã«
ã¢ããããé¢ãããå¿è³ã«å°±ããŠåã¢ã³ããã³ã§
èªçºãããäžæŽèã«å°±ããŠèšŒæããããšããã§
ã¯ãæäžæŽèäœçšãæã€ã
ã¢ããããé¢ãããå¿è³ã«å°±ããŠåã¢ã³ããã³ã§
èªçºãããäžæŽèã«å°±ããŠèšŒæããããšããã§
ã¯ãæäžæŽèäœçšãæã€ã
ãããŸã§ã«èšèŒãããè¬ççæ§è³ªã¯ãæ¬çºæã®
ã¹ãã©ã³ååç©ãããã®æ²»çãç¹ã«ç¥çµåŒç·©å€ã
ææãã€å€ãè奮å€ãéåžžçšããããé åã®æã
ã€ç¶æ è³æ©èœã®ç°åžžã®åŠçœ®ã«çšãããããšã瀺ã
ãŠãããåããããã®æäžæŽèäœçšã®æ ã«å¿èç
ã®åŠçœ®ã«çšããããšãã§ããã
ã¹ãã©ã³ååç©ãããã®æ²»çãç¹ã«ç¥çµåŒç·©å€ã
ææãã€å€ãè奮å€ãéåžžçšããããé åã®æã
ã€ç¶æ è³æ©èœã®ç°åžžã®åŠçœ®ã«çšãããããšã瀺ã
ãŠãããåããããã®æäžæŽèäœçšã®æ ã«å¿èç
ã®åŠçœ®ã«çšããããšãã§ããã
æ¬çºæã®æ°èŠã¹ãã©ã³ååç©ã¯ãæå¹æåãšã
ãŠè¬ççã«æå¹ãªéã®è©²ã¹ãã©ã³ååç©ãå«ã¿è¬
å€ãšããŠçšãããæ äœã§èããããéåžžã®åœ¢ãäŸ
ãã°é å€ãäºéå£ãŒã©ãã³ã«ãã»ã«å ¥ãå€ãã«ã
ã»ã«å€ãç³è¡£é å€ãåè¬ã泚å°å€ãã·ãããå€ã®
圢ã§çšããããšãã§ããã
ãŠè¬ççã«æå¹ãªéã®è©²ã¹ãã©ã³ååç©ãå«ã¿è¬
å€ãšããŠçšãããæ äœã§èããããéåžžã®åœ¢ãäŸ
ãã°é å€ãäºéå£ãŒã©ãã³ã«ãã»ã«å ¥ãå€ãã«ã
ã»ã«å€ãç³è¡£é å€ãåè¬ã泚å°å€ãã·ãããå€ã®
圢ã§çšããããšãã§ããã
é å€ã¯ãäŸãã°æå¹æåãšããŠã®ã¹ãã©ã³åå
ç©åã¯ãã®å¡©ã®äžã€ããä¹³ç³ããã³ãããŒã«ããœ
ã«ãããŒã«ã殿ç²ãããªããã«ãããªãã³ãã¹ã
ã¢ãªã³é žãã°ãã·ãŠã åã¯ã¢ã«ãããŠã ãã»ã«ã
ãŒã¹ç²æ«ãã³ãã€ãã«ã·ãªã«ãã¿ã«ã¯çã®åŠãåº
äœåžéå€ãšæ··åããŠããããšãã§ããã
ç©åã¯ãã®å¡©ã®äžã€ããä¹³ç³ããã³ãããŒã«ããœ
ã«ãããŒã«ã殿ç²ãããªããã«ãããªãã³ãã¹ã
ã¢ãªã³é žãã°ãã·ãŠã åã¯ã¢ã«ãããŠã ãã»ã«ã
ãŒã¹ç²æ«ãã³ãã€ãã«ã·ãªã«ãã¿ã«ã¯çã®åŠãåº
äœåžéå€ãšæ··åããŠããããšãã§ããã
é å€ã¯ç³è¡£é å€ãšåãããåŸæ¥æè¡ã«åŸã€ãŠè€
æ°å±€ã圢æããããã«è¢«èŠã«ãã€ãŠè£œé ããããš
ãã§ãããå¹æãé 延ãããããã«ãã«ã«ããã·
ã¡ãã«ã»ã«ããŒã¹ãã»ã«ããŒã¹ã¢ã»ããã¿ã¬ãŒ
ããããªé ¢é žããã«çã®åŠãéåžžã®ç©è³ªã®äžå±€å
ã¯å€å±€ã®è¢«èŠãå©çšããããšãã§ããã
æ°å±€ã圢æããããã«è¢«èŠã«ãã€ãŠè£œé ããããš
ãã§ãããå¹æãé 延ãããããã«ãã«ã«ããã·
ã¡ãã«ã»ã«ããŒã¹ãã»ã«ããŒã¹ã¢ã»ããã¿ã¬ãŒ
ããããªé ¢é žããã«çã®åŠãéåžžã®ç©è³ªã®äžå±€å
ã¯å€å±€ã®è¢«èŠãå©çšããããšãã§ããã
泚å°å€ã¯ãåèžçæ°Žããããã¬ã³ã°ãªã³ãŒã«ã
æ°Žâã¢ã«ã³ãŒã«æº¶æ¶²ã®åŠãåžéå€åã¯ãããã®æ··
åç©ã§è£œé ããããšãã§ãã奜é©ã«ã¯åœæ¥çã§äž
è¬ã«äœ¿çšãããé²è å€ã®äžããé©åœã«éžãã äžã€
ã®ãã®ãå ±åãããã
æ°Žâã¢ã«ã³ãŒã«æº¶æ¶²ã®åŠãåžéå€åã¯ãããã®æ··
åç©ã§è£œé ããããšãã§ãã奜é©ã«ã¯åœæ¥çã§äž
è¬ã«äœ¿çšãããé²è å€ã®äžããé©åœã«éžãã äžã€
ã®ãã®ãå ±åãããã
åãã飲çšå¯èœãªãã®ã¯ãäŸãã°æ¬çºæã®ã¹ã
ã©ã³ååç©ãæ°Žåã³ã°ãªã»ãªã³ã«æº¶ãããçå³å€
åã³é žåé²æ¢å€ãå ±åãããæ°Žè¬ãšããŠè£œé ã§ã
ãã
ã©ã³ååç©ãæ°Žåã³ã°ãªã»ãªã³ã«æº¶ãããçå³å€
åã³é žåé²æ¢å€ãå ±åãããæ°Žè¬ãšããŠè£œé ã§ã
ãã
çµå£çã«ãéçµå£çã«åã¯çŽè
žãžè¡ãçš®ã
ã®æ
äžåœ¢åŒã«é©åããããã¹ãŠã®é åããè¬åŠçã«å
容ããããã®ã®äžããé©åœã«éžã°ããè£å©è¬ãæ
å¹æåãšããŠçµåããããšã«ããå©çšããããšã
ã§ããã
äžåœ¢åŒã«é©åããããã¹ãŠã®é åããè¬åŠçã«å
容ããããã®ã®äžããé©åœã«éžã°ããè£å©è¬ãæ
å¹æåãšããŠçµåããããšã«ããå©çšããããšã
ã§ããã
æçšãªè¬éã¯ãåŠçœ®ãããæ£è
ããã®å¹Žä»€ãå
é¡ã®ç æ°ã®éããæäžã®éã«ãã€ãŠå€åãããã
æšæºãšããŠã¯ãæ人ã«çµå£ã§æäžããå Žåãäžå
ã«çŽ0.5ä¹è³20mgãäžæ¥ã«çŽ0.5ä¹è³90mgã®çšåºŠã§
ãããã
é¡ã®ç æ°ã®éããæäžã®éã«ãã€ãŠå€åãããã
æšæºãšããŠã¯ãæ人ã«çµå£ã§æäžããå Žåãäžå
ã«çŽ0.5ä¹è³20mgãäžæ¥ã«çŽ0.5ä¹è³90mgã®çšåºŠã§
ãããã
次ã®è«žå®æœäŸã¯æ¬çºæãäŸç€ºãããã®ã§ãã
ããæ¬çºæãå¶éãããã®ã§ã¯ãªãã
ããæ¬çºæãå¶éãããã®ã§ã¯ãªãã
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒãããã³âïŒâ
ãªã³ ã·ã¯ããã³ãã«ããšãã«ã±ãã³ãããã¢é ¢é žãš
ãã«ãåã³äºéã®æ··åç©ãå ç±ãåŸããããšã¹ã
ã«ãã«ã»ã€ã«ãªã§ããåããŠèª¿è£œãããβâã·ã¯
ããã³ãã«âβâããããã·âãããæ¡ç®é ž33ïœ
ãå°éãã€ãç¡«é ž80mlãšçºç ç¡«é žïŒH2S2O7ïŒïŒ
mlã®æ··å液äžã«ãããŸãå·åŽãã€ã€å ããã圢æ
ãããè€åäœãïŒâã§30åéãããŸãã次ãã§
300mlã®å·æ°Žã滎å ããŠå æ°Žå解ããã
âïŒâãªããµâã¹ãããïŒã»ïŒãããã³âïŒâ
ãªã³ ã·ã¯ããã³ãã«ããšãã«ã±ãã³ãããã¢é ¢é žãš
ãã«ãåã³äºéã®æ··åç©ãå ç±ãåŸããããšã¹ã
ã«ãã«ã»ã€ã«ãªã§ããåããŠèª¿è£œãããβâã·ã¯
ããã³ãã«âβâããããã·âãããæ¡ç®é ž33ïœ
ãå°éãã€ãç¡«é ž80mlãšçºç ç¡«é žïŒH2S2O7ïŒïŒ
mlã®æ··å液äžã«ãããŸãå·åŽãã€ã€å ããã圢æ
ãããè€åäœãïŒâã§30åéãããŸãã次ãã§
300mlã®å·æ°Žã滎å ããŠå æ°Žå解ããã
åŸãããæ··åç©ããšãŒãã«ã§æœåºãããšãŒãã«
å±€ãæ°Žåã³çé žãããªãŠã 10ïŒ æº¶æ¶²ã§æŽãã次ã«
ç¡«é žãããªãŠã ã®äžã§ä¹Ÿç¥ãããæžå§ã®äžã«èžç
ã«ãããšãŒãã«ãé€å»ããæ®çç©ãèžçããïŒâ
ããšãã«âïŒâãªããµâã¹ããâãïŒã»ïŒããã
ã³âïŒâãªã³ã27.3ïœåŸãïŒåç90ïŒ ïŒããã®æ§
é ã¯åæã«ãã確ãããã
å±€ãæ°Žåã³çé žãããªãŠã 10ïŒ æº¶æ¶²ã§æŽãã次ã«
ç¡«é žãããªãŠã ã®äžã§ä¹Ÿç¥ãããæžå§ã®äžã«èžç
ã«ãããšãŒãã«ãé€å»ããæ®çç©ãèžçããïŒâ
ããšãã«âïŒâãªããµâã¹ããâãïŒã»ïŒããã
ã³âïŒâãªã³ã27.3ïœåŸãïŒåç90ïŒ ïŒããã®æ§
é ã¯åæã«ãã確ãããã
13ïœã®ïŒâããšãã«âïŒâãªããµâã¹ãã
ãïŒã»ïŒãããã³âïŒâãªã³ãã容液2.5mlããã
ã«0.12ïœãã°ãã·ãŠã ãå«ãçé žã¡ãã«ãã°ãã·
ãŠã ã®ãžã¡ãã«ãã«ã ã¢ãã溶液200mlãšæ··åãã
æ··åç©ãäºé žåççŽ é°å²æ°äžã§12æé沞隰ãã
ããå€å²æž©åºŠã«å·åŽã®åŸãæ°Žãšæ°·ã®æ··åç©400ä¹
è³500ïœäžã«æ¿ãããããŸãã€ã€æ³šå ããã次ã
ã§å·åŽãã€ã€ããããã«10ïŒ å¡©é žãé žæ§ã«ãªããŸ
ã§å ããäžå€ïŒâã«æŸçœ®ããã
ãïŒã»ïŒãããã³âïŒâãªã³ãã容液2.5mlããã
ã«0.12ïœãã°ãã·ãŠã ãå«ãçé žã¡ãã«ãã°ãã·
ãŠã ã®ãžã¡ãã«ãã«ã ã¢ãã溶液200mlãšæ··åãã
æ··åç©ãäºé žåççŽ é°å²æ°äžã§12æé沞隰ãã
ããå€å²æž©åºŠã«å·åŽã®åŸãæ°Žãšæ°·ã®æ··åç©400ä¹
è³500ïœäžã«æ¿ãããããŸãã€ã€æ³šå ããã次ã
ã§å·åŽãã€ã€ããããã«10ïŒ å¡©é žãé žæ§ã«ãªããŸ
ã§å ããäžå€ïŒâã«æŸçœ®ããã
圢æãããç©è³ªãæ¿Ÿéã«ããæéãã湯济äžã§
çé žãããªãŠã ã®10ïŒ æº¶æ¶²ã§åŠçãããåå¿æ··å
ç©ãæž æ°Žã§äœåãæŽã€ãŠã«ã«ããã·ã«åãããŠã
ãªãã¹ããã©ã¯ãã³ãé€ããã10ïŒ å¡©é žã«ãã€ãŠ
é žæ§ã«ããåŸããããŸãå·åŽãã€ã€äžå€ïŒâã«æŸ
眮ããããã®ããã«ããŠåŸãããåºäœçæç©ãæ¿Ÿ
éããæ°Žã§æŽãç空äžP2O5äžã§ä¹Ÿç¥ããã
çé žãããªãŠã ã®10ïŒ æº¶æ¶²ã§åŠçãããåå¿æ··å
ç©ãæž æ°Žã§äœåãæŽã€ãŠã«ã«ããã·ã«åãããŠã
ãªãã¹ããã©ã¯ãã³ãé€ããã10ïŒ å¡©é žã«ãã€ãŠ
é žæ§ã«ããåŸããããŸãå·åŽãã€ã€äžå€ïŒâã«æŸ
眮ããããã®ããã«ããŠåŸãããåºäœçæç©ãæ¿Ÿ
éããæ°Žã§æŽãç空äžP2O5äžã§ä¹Ÿç¥ããã
ç¡æ°Žã®ãã³ãŒã³ãšç³æ²¹ãšãŒãã«ã®æ··å液ã§åçµ
æ¶ããŠãïŒâããšãã«âïŒâãªããœâïŒâãªããµ
âã¹ãã©ã³ãïŒã»ïŒãããã³âïŒâã«ã«ãã³é žã
14.8ïœåŸãïŒåç95ïŒ ïŒãèç¹ïŒŠïŒ148â150â
ïŒåè§£ïŒ åèšã®åŠãããŠåŸãããé ž21ïœãå·åŽãã€ã€ãž
ã¡ãã«ã¢ãã³ã®33ïŒ ã¢ã«ã³ãŒã«æº¶æ¶²56mlã§åŠç
ãã次ã«ãããŸãå·åŽãã€ã€35ïŒ ãã«ããªã³13ml
ã滎å ãããåŸãããæ··åç©ãå€å²æž©åºŠã§48æé
ãããŸãã次ãã§äžæé沞隰ããããæžå§ã®äžã«
溶åªãèžçºãããåŸãåŸãæ®çç©ã«æ°Žãå ããã
æ··åç©ããšãŒãã«ã§æœåºããåŸããšãŒãã«å±€ã
æ°Žã次ã«çé žãããªãŠã ïŒïŒ 溶液ã§æŽããç¡«é žã
ããªãŠã äžã§ä¹Ÿç¥ããããšãŒãã«ãšïœâãã³ã¿ã³
ã®æ··å溶åªã§åçµæ¶ããåŸã17.7ïœã®ïŒâïŒãžã¡
ãã«ã¢ãããšãã«ïŒâïŒâããšãã«âïŒâãªããµ
âã¹ãããïŒã»ïŒãããã³âïŒâãªã³ãåŸãïŒå
ç81ïŒ ïŒãèç¹ïŒŠïŒ76â77âã
æ¶ããŠãïŒâããšãã«âïŒâãªããœâïŒâãªããµ
âã¹ãã©ã³ãïŒã»ïŒãããã³âïŒâã«ã«ãã³é žã
14.8ïœåŸãïŒåç95ïŒ ïŒãèç¹ïŒŠïŒ148â150â
ïŒåè§£ïŒ åèšã®åŠãããŠåŸãããé ž21ïœãå·åŽãã€ã€ãž
ã¡ãã«ã¢ãã³ã®33ïŒ ã¢ã«ã³ãŒã«æº¶æ¶²56mlã§åŠç
ãã次ã«ãããŸãå·åŽãã€ã€35ïŒ ãã«ããªã³13ml
ã滎å ãããåŸãããæ··åç©ãå€å²æž©åºŠã§48æé
ãããŸãã次ãã§äžæé沞隰ããããæžå§ã®äžã«
溶åªãèžçºãããåŸãåŸãæ®çç©ã«æ°Žãå ããã
æ··åç©ããšãŒãã«ã§æœåºããåŸããšãŒãã«å±€ã
æ°Žã次ã«çé žãããªãŠã ïŒïŒ 溶液ã§æŽããç¡«é žã
ããªãŠã äžã§ä¹Ÿç¥ããããšãŒãã«ãšïœâãã³ã¿ã³
ã®æ··å溶åªã§åçµæ¶ããåŸã17.7ïœã®ïŒâïŒãžã¡
ãã«ã¢ãããšãã«ïŒâïŒâããšãã«âïŒâãªããµ
âã¹ãããïŒã»ïŒãããã³âïŒâãªã³ãåŸãïŒå
ç81ïŒ ïŒãèç¹ïŒŠïŒ76â77âã
å æ C17H23NO2ïŒ273ã362ïŒ
èšç®å€ïŒ
ïŒ74.69 ïŒ8.48 ïŒ5.12
å®éšå€ïŒ
ïŒ74.44 ïŒ8.30 ïŒ4.93
çæç©ã®æ§é ã¯IRåã³NMRã¹ãã¯ãã«ã§ç¢ºã
ãããã
ãããã
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâ
ãªã³ βâã·ã¯ããã³ãã«âβâããããã·âããã
æ¡ç®é žã®ä»£ãã«ãβâã·ã¯ãããã·ã«âβâãã
ããã·âãããæ¡ç®é žãçšããŠå®æœäŸïŒã®æäœã
è¡ã€ããè€åäœã®å æ°Žå解ã®éã«ãç²çš ãªçæç©
ã圢æããããããã®ãã®ã¯å·åŽãšããããšã«ã
ãçµæ¶åãããæ¿Ÿéãæ°Žãšïœâãã³ã¿ã³ã«ããæŽ
æµãP2O5äžã§ã®ä¹Ÿç¥ããšãŒãã«ãšïœâãã³ã¿ã³
ã®æ··å液ããã®åçµæ¶ã®åŸã99ïŒ ã®åçã§ïŒâã
ãšãã«âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³â
ïŒâãªã³ãåŸããèç¹ïŒŠïŒ104â105âã
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâ
ãªã³ βâã·ã¯ããã³ãã«âβâããããã·âããã
æ¡ç®é žã®ä»£ãã«ãβâã·ã¯ãããã·ã«âβâãã
ããã·âãããæ¡ç®é žãçšããŠå®æœäŸïŒã®æäœã
è¡ã€ããè€åäœã®å æ°Žå解ã®éã«ãç²çš ãªçæç©
ã圢æããããããã®ãã®ã¯å·åŽãšããããšã«ã
ãçµæ¶åãããæ¿Ÿéãæ°Žãšïœâãã³ã¿ã³ã«ããæŽ
æµãP2O5äžã§ã®ä¹Ÿç¥ããšãŒãã«ãšïœâãã³ã¿ã³
ã®æ··å液ããã®åçµæ¶ã®åŸã99ïŒ ã®åçã§ïŒâã
ãšãã«âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³â
ïŒâãªã³ãåŸããèç¹ïŒŠïŒ104â105âã
ãã®ããã«ããŠåŸãããã¹ããã©ã¯ãã³ããå®
æœäŸïŒã«ç€ºãããåŠããçé žã¡ãã«ãã°ãã·ãŠã
ã®ãžã¡ãã«ãã«ã ã¢ãã溶液ãšæ··åã沞隰ããã
åŠçãããããã®ããã«ããŠãåç86ïŒ ã§ïŒâã
ãšãã«âïŒâãªããœâïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâã«ã«ãã³é žãåŸããèç¹ïŒŠïŒ
158â160âïŒå解ïŒã
æœäŸïŒã«ç€ºãããåŠããçé žã¡ãã«ãã°ãã·ãŠã
ã®ãžã¡ãã«ãã«ã ã¢ãã溶液ãšæ··åã沞隰ããã
åŠçãããããã®ããã«ããŠãåç86ïŒ ã§ïŒâã
ãšãã«âïŒâãªããœâïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâã«ã«ãã³é žãåŸããèç¹ïŒŠïŒ
158â160âïŒå解ïŒã
ãã®ããã«ããŠåŸãããé
žããå®æœäŸïŒã«ç€ºã
ããåŠãããžã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ã§åŠ
çããŠãåç91ïŒ ã§ïŒâïŒãžã¡ãã«ã¢ããã¡ã
ã«ïŒâïŒâããšãã«âïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâãªã³ãåŸããèç¹ïŒŠïŒ117â119
â å æ C18H25NO2ïŒ287â368ïŒ èšç®å€ïŒ ïŒ75.22 ïŒ8.77 ïŒ4.87 å®éšå€ïŒ ïŒ75.48 ïŒ8.67 ïŒ5.04 éåžžã®æ¹æ³ã§ãããªãã¡å¡©åæ°ŽçŽ é žã®ãšã¿ããŒ
ã«æº¶æ¶²ãå¡©åºã®ãšãŒãã«æº¶æ¶²ã«å ããŠå¡©é žå¡©ã調
補ãããå¡©é žå¡©ã®èç¹ïŒŠã¯206â207âã§ãã€ãã
ããåŠãããžã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ã§åŠ
çããŠãåç91ïŒ ã§ïŒâïŒãžã¡ãã«ã¢ããã¡ã
ã«ïŒâïŒâããšãã«âïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâãªã³ãåŸããèç¹ïŒŠïŒ117â119
â å æ C18H25NO2ïŒ287â368ïŒ èšç®å€ïŒ ïŒ75.22 ïŒ8.77 ïŒ4.87 å®éšå€ïŒ ïŒ75.48 ïŒ8.67 ïŒ5.04 éåžžã®æ¹æ³ã§ãããªãã¡å¡©åæ°ŽçŽ é žã®ãšã¿ããŒ
ã«æº¶æ¶²ãå¡©åºã®ãšãŒãã«æº¶æ¶²ã«å ããŠå¡©é žå¡©ã調
補ãããå¡©é žå¡©ã®èç¹ïŒŠã¯206â207âã§ãã€ãã
å æ C18H26ClNO2ïŒ323ã853ïŒ
èšç®å€ïŒ
ïŒ66.75 ïŒ8.09 ClïŒ10.95
ïŒ4.33
å®éšå€ïŒ
ïŒ66.36 ïŒ7.83 ClïŒ11.30
ïŒ4.23
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã
ãªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³
âïŒâãªã³ βâã·ã¯ããã³ãã«âβâããããã·âããã
æ¡ç®é žã®ä»£ãã«ïœâã¡ãã«âβâã·ã¯ãããã·ã«
âβâããããã·âãããæ¡ç®é žãçšããŠãå®æœ
äŸïŒã«ç€ºãããæäœãè¡ããåç92ïŒ ã§ïŒâïŒïœ
âããªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«
ã³âïŒâãªã³ãåŸããèç¹ïŒŠïŒ92â93âã
ãªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³
âïŒâãªã³ βâã·ã¯ããã³ãã«âβâããããã·âããã
æ¡ç®é žã®ä»£ãã«ïœâã¡ãã«âβâã·ã¯ãããã·ã«
âβâããããã·âãããæ¡ç®é žãçšããŠãå®æœ
äŸïŒã«ç€ºãããæäœãè¡ããåç92ïŒ ã§ïŒâïŒïœ
âããªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«
ã³âïŒâãªã³ãåŸããèç¹ïŒŠïŒ92â93âã
ãã®ããã«ããŠåŸãã¹ããã©ã¯ãã³ããå®æœäŸ
ïŒã«ç€ºãããããã«ãçé žã¡ãã«ãã°ãã·ãŠã ã®
ãžã¡ãã«ãã«ã ã¢ãã溶液ãšæ··åã沞隰ãããŠåŠ
çããããã®ããã«ããŠãåç79ïŒ ã§ïŒâïŒïœâ
ããªã«ïŒâïŒâãªããœâïŒâãªããµâã¹ãã
ãïŒã»ïŒããã«ã³âïŒâã«ã«ãã³é žãåŸããèç¹
ïŒ171â172âïŒå解ïŒã
ïŒã«ç€ºãããããã«ãçé žã¡ãã«ãã°ãã·ãŠã ã®
ãžã¡ãã«ãã«ã ã¢ãã溶液ãšæ··åã沞隰ãããŠåŠ
çããããã®ããã«ããŠãåç79ïŒ ã§ïŒâïŒïœâ
ããªã«ïŒâïŒâãªããœâïŒâãªããµâã¹ãã
ãïŒã»ïŒããã«ã³âïŒâã«ã«ãã³é žãåŸããèç¹
ïŒ171â172âïŒå解ïŒã
åèšã®åŠãããŠåŸãããé
žãå·åŽãã€ã€ãå®æœ
äŸïŒã«ç€ºãããããã«ãã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒ
ã«æº¶æ¶²ã§åŠçããããã®ããã«ããŠãåç60ïŒ ã§
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒ
âãªã³ãåŸããèç¹ïŒŠïŒ133â134â å æ C19H27NO2ïŒ301ã414ïŒ èšç®å€ïŒ ïŒ75.71 ïŒ9.03 ïŒ4.65 å®éšå€ïŒ ïŒ75.76 ïŒ9.07 ïŒ4.65 ãã®ååç©ã®å¡©é žå¡©ã®èç¹ïŒŠã¯221â222âã§ã
ã€ãã
äŸïŒã«ç€ºãããããã«ãã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒ
ã«æº¶æ¶²ã§åŠçããããã®ããã«ããŠãåç60ïŒ ã§
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒ
âãªã³ãåŸããèç¹ïŒŠïŒ133â134â å æ C19H27NO2ïŒ301ã414ïŒ èšç®å€ïŒ ïŒ75.71 ïŒ9.03 ïŒ4.65 å®éšå€ïŒ ïŒ75.76 ïŒ9.07 ïŒ4.65 ãã®ååç©ã®å¡©é žå¡©ã®èç¹ïŒŠã¯221â222âã§ã
ã€ãã
å æ C19H28ClNO2ïŒ337ã879ïŒ
èšç®å€ïŒ
ïŒ67.54 ïŒ8.35 ClïŒ10.19
ïŒ4.15
å®éšå€ïŒ
ïŒ67.28 ïŒ8.11 ClïŒ10.29
ïŒ4.44
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒãããã³âïŒâ
ãªã³ã®ãšãŒãã¡ãã©ãŒã å®æœäŸïŒã®æ¹æ³ã§åŸããã5.5ïœã®ïŒâïŒãžã¡
ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµ
âã¹ãããïŒã»ïŒãããã³âïŒâãªã³ããïŒmlã®
ãšãŠåã¡ãã«ã®å ±åã®äžã«ã60mlã®ç¡æ°Žã®ã¢ã»ã
ã³äžå€å²æž©åºŠã§72æéãããŸãããæŽã«ãšãŠåã¡
ãã«ïŒmlãå ããæ··åç©ãïŒæé沞隰ããããå€
å²æž©åºŠã«å·åŽã®åŸãç¡æ°Žã®ãšãŒãã«ãå ããã圢
æãããå¡©ãæ¿Ÿéãããšã¿ããŒã«ãšç¡æ°Žã®ãšãŒã
ã«ãšã®æ··å液ããåçµæ¶ãããã
âïŒâãªããµâã¹ãããïŒã»ïŒãããã³âïŒâ
ãªã³ã®ãšãŒãã¡ãã©ãŒã å®æœäŸïŒã®æ¹æ³ã§åŸããã5.5ïœã®ïŒâïŒãžã¡
ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµ
âã¹ãããïŒã»ïŒãããã³âïŒâãªã³ããïŒmlã®
ãšãŠåã¡ãã«ã®å ±åã®äžã«ã60mlã®ç¡æ°Žã®ã¢ã»ã
ã³äžå€å²æž©åºŠã§72æéãããŸãããæŽã«ãšãŠåã¡
ãã«ïŒmlãå ããæ··åç©ãïŒæé沞隰ããããå€
å²æž©åºŠã«å·åŽã®åŸãç¡æ°Žã®ãšãŒãã«ãå ããã圢
æãããå¡©ãæ¿Ÿéãããšã¿ããŒã«ãšç¡æ°Žã®ãšãŒã
ã«ãšã®æ··å液ããåçµæ¶ãããã
ãã®ããã«ããŠãšãŒãã¡ãã©ãŒã7.7ïœïŒåç
93ïŒ ïŒãåŸããèç¹ïŒŠïŒ185â186â å æ C18H26ClNO2ïŒ415ã306ïŒ èšç®å€ïŒ ïŒ52.05 ïŒ6.31 ïŒ30.56 ïŒ3.37 å®éšå€ïŒ ïŒ51.67 ïŒ6.37 ïŒ30.62 ïŒ3.55 å®æœäŸ ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâ
ãªã³âãšãŒãã¡ãã©ãŒã å®æœäŸïŒã«ç€ºãããæ¹æ³ã§åŸãããã¹ããã©ã¯
ãã³ãåºçºäœãšããŠãå®æœäŸïŒã«ç€ºããããããª
æäœãè¡ã€ãããã®ããã«ããŠãåç94ïŒ ã§ãšãŒ
ãã¡ãã©ãŒããåŸããããèç¹ïŒŠïŒ218â220â å æ C19H28ClNO2ïŒ429ã332ïŒ èšç®å€ïŒ ïŒ53.15 ïŒ6.57 ïŒ29.56 ïŒ3.26 å®éšå€ïŒ ïŒ53.18 ïŒ6.53 ïŒ29.50 ïŒ3.42 å®æœäŸ ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ 150mlã®ç¡æ°ŽãšãŒãã«äžã®17ïœã®ïŒâïŒãžã¡ã
ã«ã¢ããã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµâ
ã¹ãããïŒã»ïŒããã«ã³âïŒâãªã³ã®æº¶æ¶²ããã
ããŸãã€ã€åŸã ã«ã300mlã®ç¡æ°Žããã©ãããã
ã©ã³äžã®ïŒïœã®æ°ŽçŽ åãªããŠã ã¢ã«ãããŠã ã®æž
æ¿æ¶²äžã«å ããã次ãã§æ··åç©ãïŒæé沞隰ãã
ãã圢æãããè€åäœããäœæž©ã§ãããŸãã€ã€æ°Ž
åã³10ïŒ ã®çé žãããªãŠã 溶液ã滎å ããŠãå æ°Ž
å解ãããæ°Žé žåã¢ã«ãããŠã åã³æ°Žé žåãªããŠ
ã ãæ¿Ÿå¥ããåŸã溶åªãæžå§ã§èžçºãããå·åŽã«
ããåºäœåããæ®çç©ããšãŒãã«ãšïœâãã³ã¿ã³
ã®æº¶å溶åªããåçµæ¶ãããã
93ïŒ ïŒãåŸããèç¹ïŒŠïŒ185â186â å æ C18H26ClNO2ïŒ415ã306ïŒ èšç®å€ïŒ ïŒ52.05 ïŒ6.31 ïŒ30.56 ïŒ3.37 å®éšå€ïŒ ïŒ51.67 ïŒ6.37 ïŒ30.62 ïŒ3.55 å®æœäŸ ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâ
ãªã³âãšãŒãã¡ãã©ãŒã å®æœäŸïŒã«ç€ºãããæ¹æ³ã§åŸãããã¹ããã©ã¯
ãã³ãåºçºäœãšããŠãå®æœäŸïŒã«ç€ºããããããª
æäœãè¡ã€ãããã®ããã«ããŠãåç94ïŒ ã§ãšãŒ
ãã¡ãã©ãŒããåŸããããèç¹ïŒŠïŒ218â220â å æ C19H28ClNO2ïŒ429ã332ïŒ èšç®å€ïŒ ïŒ53.15 ïŒ6.57 ïŒ29.56 ïŒ3.26 å®éšå€ïŒ ïŒ53.18 ïŒ6.53 ïŒ29.50 ïŒ3.42 å®æœäŸ ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ 150mlã®ç¡æ°ŽãšãŒãã«äžã®17ïœã®ïŒâïŒãžã¡ã
ã«ã¢ããã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµâ
ã¹ãããïŒã»ïŒããã«ã³âïŒâãªã³ã®æº¶æ¶²ããã
ããŸãã€ã€åŸã ã«ã300mlã®ç¡æ°Žããã©ãããã
ã©ã³äžã®ïŒïœã®æ°ŽçŽ åãªããŠã ã¢ã«ãããŠã ã®æž
æ¿æ¶²äžã«å ããã次ãã§æ··åç©ãïŒæé沞隰ãã
ãã圢æãããè€åäœããäœæž©ã§ãããŸãã€ã€æ°Ž
åã³10ïŒ ã®çé žãããªãŠã 溶液ã滎å ããŠãå æ°Ž
å解ãããæ°Žé žåã¢ã«ãããŠã åã³æ°Žé žåãªããŠ
ã ãæ¿Ÿå¥ããåŸã溶åªãæžå§ã§èžçºãããå·åŽã«
ããåºäœåããæ®çç©ããšãŒãã«ãšïœâãã³ã¿ã³
ã®æº¶å溶åªããåçµæ¶ãããã
ãã®ããã«ããŠãåç87ïŒ
ã§ïŒïŒâããšãã«â
ïŒâãžã¡ãã«ã¢ããã¡ãã«âïŒâããããã·ïŒâ
ïŒâãããã«âã·ã¯ããããµããŒã«ãåŸããèç¹
ïŒ146â147â åèšã®åŠãããŠåŸãããã¢ããâãžãªãŒã«ã
300mlã®ç¡æ°Žããªãžã³äžã®æº¶æ¶²ãšãããããŸãå·
åŽãã€ã€ãããã«10.4ïœã®å¡©åïœâããã¢ãã³ãŒ
ã³ã¹ã«ããã«ãå°éãã€çžæ¬¡ãã§æ·»å ãããæ··å
ç©ãå€å²æž©åºŠã§20æéãããŸãã次ã«æ°Žã®äžã«æ³š
å ¥ãããã¯ãããã«ã ã§æœåºããã¯ãããã«ã å±€
ãæ°Žã§æŽãã次ãã§ç¡«é žãããªãŠã äžã§ä¹Ÿç¥ã
ããç空äžã§æº¶åªãé€å»ããæ®çç©ãäžæ§ã¢ã«ã
ãã®ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒ30ïœã®ã¢ã«ãã
ã«å¯Ÿãæ®çç©ïŒïœïŒã«ããã溶åºå€ãšããŠãšãŒã
ã«ãçšãããçžåœãããã©ã¯ã·ãšã³ãèžçºããã
ãšãŒãã«ãšïœâãã³ã¿ã³ã®æ··å液ããåçµæ¶ãã
ãŠç²Ÿè£œããåŸãåç78ïŒ ã§ãïŒâïŒãžã¡ãã«ã¢ã
ãã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµâã¹ãã
ãïŒã»ïŒããã«ã³ãåŸããèç¹ïŒŠïŒ65âã
ïŒâãžã¡ãã«ã¢ããã¡ãã«âïŒâããããã·ïŒâ
ïŒâãããã«âã·ã¯ããããµããŒã«ãåŸããèç¹
ïŒ146â147â åèšã®åŠãããŠåŸãããã¢ããâãžãªãŒã«ã
300mlã®ç¡æ°Žããªãžã³äžã®æº¶æ¶²ãšãããããŸãå·
åŽãã€ã€ãããã«10.4ïœã®å¡©åïœâããã¢ãã³ãŒ
ã³ã¹ã«ããã«ãå°éãã€çžæ¬¡ãã§æ·»å ãããæ··å
ç©ãå€å²æž©åºŠã§20æéãããŸãã次ã«æ°Žã®äžã«æ³š
å ¥ãããã¯ãããã«ã ã§æœåºããã¯ãããã«ã å±€
ãæ°Žã§æŽãã次ãã§ç¡«é žãããªãŠã äžã§ä¹Ÿç¥ã
ããç空äžã§æº¶åªãé€å»ããæ®çç©ãäžæ§ã¢ã«ã
ãã®ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒ30ïœã®ã¢ã«ãã
ã«å¯Ÿãæ®çç©ïŒïœïŒã«ããã溶åºå€ãšããŠãšãŒã
ã«ãçšãããçžåœãããã©ã¯ã·ãšã³ãèžçºããã
ãšãŒãã«ãšïœâãã³ã¿ã³ã®æ··å液ããåçµæ¶ãã
ãŠç²Ÿè£œããåŸãåç78ïŒ ã§ãïŒâïŒãžã¡ãã«ã¢ã
ãã¡ãã«ïŒâïŒâããšãã«âïŒâãªããµâã¹ãã
ãïŒã»ïŒããã«ã³ãåŸããèç¹ïŒŠïŒ65âã
å æ C18H27NO2ïŒ273ã404ïŒ
èšç®å€ïŒ
ïŒ79.07 ïŒšïŒ 9.95 ïŒ5.12
å®éšå€ïŒ
ïŒ79.14 ïŒ10.14 ïŒ5.01
éåžžã®æ¹æ³ã§çžåœããå¡©é
žå¡©ã調æ»ãããèç¹
201â202âã
201â202âã
å æ C18H28ClNOïŒ309ã869ïŒ
èšç®å€ïŒ
ïŒ69.76 ïŒ9.11 ClïŒ11.44
ïŒ4.52
å®éšå€ïŒ
ïŒ69.79 ïŒ8.79 ClïŒ11.36
ïŒ4.47
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã¯
ããããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒãããã³âïŒâãªã³ ãã®ååç©ã¯ãã·ã¯ããã³ãã«ããšãã«ã±ãã³
ã®ä»£ãã«ã·ã¯ããã³ãã«âïŒïœâã¯ããããšã
ã«ïŒâã±ãã³ïŒãã«ã®ãŒç¹èš±ç¬¬634208å·èšèŒïŒã
åºçºç©è³ªãšããŠçšããå®æœäŸïŒãšåãæäœã«ãã
åŸããããβâã·ã¯ããã³ãã«âβâããããã·
â4â²âã¯ããâãããæ¡ç®é žã圢æããããã®ã
ã®ãïŒâïŒïœâã¯ããâããšãã«ïŒâïŒâãªããµ
âã¹ããã4.4ãããã³âïŒâãªã³ã«ååŠå€åã
ããã
ããããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒãããã³âïŒâãªã³ ãã®ååç©ã¯ãã·ã¯ããã³ãã«ããšãã«ã±ãã³
ã®ä»£ãã«ã·ã¯ããã³ãã«âïŒïœâã¯ããããšã
ã«ïŒâã±ãã³ïŒãã«ã®ãŒç¹èš±ç¬¬634208å·èšèŒïŒã
åºçºç©è³ªãšããŠçšããå®æœäŸïŒãšåãæäœã«ãã
åŸããããβâã·ã¯ããã³ãã«âβâããããã·
â4â²âã¯ããâãããæ¡ç®é žã圢æããããã®ã
ã®ãïŒâïŒïœâã¯ããâããšãã«ïŒâïŒâãªããµ
âã¹ããã4.4ãããã³âïŒâãªã³ã«ååŠå€åã
ããã
çžåœããé
žïŒïŒŠïŒ153â155âïŒãå®æœäŸïŒã«ç€º
ãããåŠã圢æãããåŸããã«ããªã³ã®ååšã®äž
ã«ãžã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ãäœçšãã
ãŠãç®çã®ååç©ãåŸããèç¹ïŒŠïŒ92â94âïŒãš
ãŒãã«âïœâãã³ã¿ã³ïŒã
ãããåŠã圢æãããåŸããã«ããªã³ã®ååšã®äž
ã«ãžã¡ãã«ã¢ãã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ãäœçšãã
ãŠãç®çã®ååç©ãåŸããèç¹ïŒŠïŒ92â94âïŒãš
ãŒãã«âïœâãã³ã¿ã³ïŒã
å®æœäŸ ïŒ
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã¯
ããããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒãããã³ã®å¡©é žå¡© ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâãª
ã³ã®ä»£ãã«ãïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒ
âïŒïœâã¯ããããšãã«ïŒâïŒâãªããµâã¹ãã
ãïŒã»ïŒãããã³âïŒâãªã³ãçšããå®æœäŸïŒã«
瀺ãããããã«æäœãè¡ã€ãã該ã¹ããããªã³ãª
ã³ããç¡æ°Žããã©ããããã©ã³äžã®æ°ŽçŽ åãªããŠ
ã ã¢ã«ãããŠã ã®æžæ¿æ¶²ã«åŸã ã«å ããã
ããããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒãããã³ã®å¡©é žå¡© ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšãã«
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâãª
ã³ã®ä»£ãã«ãïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒ
âïŒïœâã¯ããããšãã«ïŒâïŒâãªããµâã¹ãã
ãïŒã»ïŒãããã³âïŒâãªã³ãçšããå®æœäŸïŒã«
瀺ãããããã«æäœãè¡ã€ãã該ã¹ããããªã³ãª
ã³ããç¡æ°Žããã©ããããã©ã³äžã®æ°ŽçŽ åãªããŠ
ã ã¢ã«ãããŠã ã®æžæ¿æ¶²ã«åŸã ã«å ããã
åŸãããã¢ããâãžãªãŒã«ããããªãžã³äžã®å¡©
åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«ããã
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã¯ã
ãããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ãã³âïŒâãªã³ã«å€åãããã
åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«ããã
ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã¯ã
ãããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ãã³âïŒâãªã³ã«å€åãããã
次ãã§ããšã¿ããŒã«âãšãŒãã«æ··å液äžã®æº¶æ¶²
ãšããŠãå¡©é žãäœçšããç®çã®å¡©é žå¡©ãåŸããè
ç¹ïŒŠïŒ221â223âã
ãšããŠãå¡©é žãäœçšããç®çã®å¡©é žå¡©ãåŸããè
ç¹ïŒŠïŒ221â223âã
å®æœäŸ ïŒ
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ãã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ã«ã³âïŒâãªã³ã®å¡©é žå¡© ã·ã¯ããã³ãã«ããšãã«ã±ãã³ã®ä»£ãã«ãã·ã¯
ãããã·ã«âïŒïœâã¯ããããšãã«ïŒã±ãã³ïŒç±³
åœç¹èš±ç¬¬3308159å·èšèŒïŒãåºçºååç©ãšããŠçš
ããå®æœäŸïŒã«ç€ºãããåŠãæäœãè¡ã€ãããã®
ããã«ããŠÎ²âã·ã¯ãããã·ã«âβâããããã·
â4â²âã¯ããâãããæ¡ç®é žã圢æããããã®ã
ã®ãïŒâïŒïœâã¯ããããšãã«ïŒâïŒâãªããµâ
ã¹ãããïŒã»ïŒããã«ã³âïŒâãªã³ã«ååŠå€åã
ããã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ã«ã³âïŒâãªã³ã®å¡©é žå¡© ã·ã¯ããã³ãã«ããšãã«ã±ãã³ã®ä»£ãã«ãã·ã¯
ãããã·ã«âïŒïœâã¯ããããšãã«ïŒã±ãã³ïŒç±³
åœç¹èš±ç¬¬3308159å·èšèŒïŒãåºçºååç©ãšããŠçš
ããå®æœäŸïŒã«ç€ºãããåŠãæäœãè¡ã€ãããã®
ããã«ããŠÎ²âã·ã¯ãããã·ã«âβâããããã·
â4â²âã¯ããâãããæ¡ç®é žã圢æããããã®ã
ã®ãïŒâïŒïœâã¯ããããšãã«ïŒâïŒâãªããµâ
ã¹ãããïŒã»ïŒããã«ã³âïŒâãªã³ã«ååŠå€åã
ããã
å®æœäŸïŒã«èšèŒãããæè¡ã«ãã€ãŠãçžåœãã
é žïŒïŒŠïŒ156â159âãå解ïŒã圢æãããåŸãã
ããªãžã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ãäœçšãããïŒââ
ãããªãžãã¡ãã«âïŒâïŒïœâã¯ããããšãã«ïŒ
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâãª
ã³ãåŸãããã®ãã®ããšã¿ããŒã«âãžãšãã«ãšãŒ
ãã«ã®æ··å液äžã§å¡©é žã®äœçšã«ããå¡©é žå¡©ã«å€å
ããããèç¹ïŒŠïŒ214â216âïŒå解ïŒã
é žïŒïŒŠïŒ156â159âãå解ïŒã圢æãããåŸãã
ããªãžã³ã®ã¢ã«ã³ãŒã«æº¶æ¶²ãäœçšãããïŒââ
ãããªãžãã¡ãã«âïŒâïŒïœâã¯ããããšãã«ïŒ
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâãª
ã³ãåŸãããã®ãã®ããšã¿ããŒã«âãžãšãã«ãšãŒ
ãã«ã®æ··å液äžã§å¡©é žã®äœçšã«ããå¡©é žå¡©ã«å€å
ããããèç¹ïŒŠïŒ214â216âïŒå解ïŒã
å®æœäŸ 10
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ãã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ã«ãã«ã³ã®å¡©é žå¡© ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ãã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«
ã³âïŒâãªã³ãçšããå®æœäŸïŒã«ç€ºãããåŠãæ
äœãè¡ã€ãã該ã¹ãããã«ã³ãªã³ããç¡æ°Žããã
ãã©ã³äžã®æ°Žé žåãªããŠã ã¢ã«ãããŠã ã®æžæ¿æ¶²
äžã«åŸã ã«å ããã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ã«ãã«ã³ã®å¡©é žå¡© ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ãã
ããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«
ã³âïŒâãªã³ãçšããå®æœäŸïŒã«ç€ºãããåŠãæ
äœãè¡ã€ãã該ã¹ãããã«ã³ãªã³ããç¡æ°Žããã
ãã©ã³äžã®æ°Žé žåãªããŠã ã¢ã«ãããŠã ã®æžæ¿æ¶²
äžã«åŸã ã«å ããã
åŸãããã¢ãã³âãžãªãŒã«ããããªãžã³äžã®å¡©
åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«ããã
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ããã
ãšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³
ã«å€åãããã
åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«ããã
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ããã
ãšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³
ã«å€åãããã
éåžžã®æè¡ã«åŸããå¡©é
žã®äœçšã«ãããšã¿ããŒ
ã«âãšãŒãã«æ··å液äžã§å¡©é žå¡©ãåŸããèç¹ïŒŠïŒ
281â283âã
ã«âãšãŒãã«æ··å液äžã§å¡©é žå¡©ãåŸããèç¹ïŒŠïŒ
281â283âã
å®æœäŸ 11
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³â
ïŒâãªã³ã®å¡©é žå¡© å®æœäŸïŒã«ç€ºãããæäœã«åŸããåºçºååç©ãš
ããŠã¯ã·ã¯ãããã·ã«âïŒïœâããªã«ïŒã±ãã³ã
çšãããã®çæç©ãåŸãããšã¿ããŒã«âãžãšãã«
ãšãŒãã«æ··å液äžã§ïŒââãããªãžãã¡ãã«â
ïŒâïŒïœâããªã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâãªã³ãå¡©é žã®äœçšã«ãããã®å¡©
é žå¡©ã«å€åããããèç¹ïŒŠïŒ214â216âïŒå解ïŒã
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³â
ïŒâãªã³ã®å¡©é žå¡© å®æœäŸïŒã«ç€ºãããæäœã«åŸããåºçºååç©ãš
ããŠã¯ã·ã¯ãããã·ã«âïŒïœâããªã«ïŒã±ãã³ã
çšãããã®çæç©ãåŸãããšã¿ããŒã«âãžãšãã«
ãšãŒãã«æ··å液äžã§ïŒââãããªãžãã¡ãã«â
ïŒâïŒïœâããªã«ïŒâïŒâãªããµâã¹ãããïŒã»
ïŒããã«ã³âïŒâãªã³ãå¡©é žã®äœçšã«ãããã®å¡©
é žå¡©ã«å€åããããèç¹ïŒŠïŒ214â216âïŒå解ïŒã
å®æœäŸ 12
ïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ã®
å¡©é žå¡© ïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒ
âãªã³ãçšãå®æœäŸïŒã«ç€ºãããæäœãè¡ã€ãã
ãã®ã¹ãããã«ã³ãªã³ããç¡æ°Žããã©ããããã©
ã³äžã®æ°ŽçŽ åãªããŠã ã¢ã«ãããŠã ã®æžæ¿æ¶²ã«
åŸã ã«å ããŠãçžåœããã¢ããâãžãªãŒã«ã圢æ
ãããã
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ã®
å¡©é žå¡© ïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒ
âãªã³ãçšãå®æœäŸïŒã«ç€ºãããæäœãè¡ã€ãã
ãã®ã¹ãããã«ã³ãªã³ããç¡æ°Žããã©ããããã©
ã³äžã®æ°ŽçŽ åãªããŠã ã¢ã«ãããŠã ã®æžæ¿æ¶²ã«
åŸã ã«å ããŠãçžåœããã¢ããâãžãªãŒã«ã圢æ
ãããã
ãã®ã¢ããâãžãªãŒã«ããåºçºããŠãããªãžã³
äžã®å¡©åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«
ããïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ãåŸ
ãã
äžã®å¡©åïœâããã¢ãã³ãŒã³ã¹ã«ããã«ã®äœçšã«
ããïŒââãããªãžãã¡ãã«âïŒâïŒïœâããª
ã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ãåŸ
ãã
次ãã§ãéåžžã®æ¹æ³ã§å¡©é
žãäœçšããå¡©é
žå¡©ã
調補ããããšã¿ããŒã«âãžãšãã«ãšãŒãã«æ··å液
ã§æ§æããã溶åªã§å¡©é žå¡©ãæœåºãããèç¹ïŒŠïŒ
283â286âïŒå解ïŒã
調補ããããšã¿ããŒã«âãžãšãã«ãšãŒãã«æ··å液
ã§æ§æããã溶åªã§å¡©é žå¡©ãæœåºãããèç¹ïŒŠïŒ
283â286âïŒå解ïŒã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ããã®åŒäžãã¯æ°ŽçŽ åååã¯ããã²ã³ååãæ
ãã¯ã¢ã«ãã«åºã§ããïŒR1ãšR2ã¯åäžåã¯ç°ãª
ããã®ã§ãã€ãŠãããããæ°ŽçŽ åååã¯ã¢ã«ãã«
åºãè¡šãããæãã¯R1ãšR2ãäžã€ã«ãªã€ãŠå«çª
çŽ è¢«çŽ ç°ã圢æãïŒïŒ¡ã¯CH2åºåã¯COåºã
è¡šããïŒïœã¯ïŒåã¯ïŒã§ãããã ãæã€ã¹ãã©ã³èªå°äœã ïŒ ïŒ¡ãCOåºã§ããããæ°ŽçŽ åååã¯ãã
ã²ã³ååãæãã¯ã¡ãã«åºã§ããããšãç¹åŸŽãšã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ã¹ãã©ã³èªå°äœã ïŒ ïŒ¡ãCH2åºã§ããããæ°ŽçŽ åååã¯ãã
ã²ã³ååãæã¯ã¡ãã«åºã§ããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ã¹ãã©ã³èªå°äœã ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšã
ã«âïŒâãªããµâã¹ãããïŒã»ïŒãããã³âïŒâ
ãªã³ãïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããš
ãã«âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒ
âãªã³ãïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâ
ïŒïœâããªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒã
ãã«ã³âïŒâãªã³ãïŒâïŒãžã¡ãã«ã¢ããã¡ã
ã«ïŒâïŒâïŒïœâã¯ããããšãã«ïŒâïŒâãªããµ
âã¹ãããïŒã»ïŒãããã³âïŒâãªã³ãïŒââ
ãããªãžãã¡ãã«âïŒâïŒïœâã¯ããããšãã«ïŒ
âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³âïŒâãª
ã³ãåã³ïŒââãããªãžãã¡ãã«âïŒâïŒïœâ
ããªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³
âïŒâãªã³ããéžã°ããããšãç¹åŸŽãšããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ã¹ãã©ã³èªå°äœã ïŒ ïŒâïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâããšã
ã«âïŒâãªããµâã¹ãããïŒã»ïŒããã«ã³ãïŒâ
ïŒãžã¡ãã«ã¢ããã¡ãã«ïŒâïŒâïŒïœâã¯ããã
ãšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã
ã³ãïŒââãããªãžãã¡ãã«âïŒâïŒïœâã¯ã
ãããšãã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒãã
ã«ã³ãåã³ïŒââãããªãžãã¡ãã«âïŒâïŒïœ
âããªã«ïŒâïŒâãªããµâã¹ãããïŒã»ïŒããã«
ã³ããéžã°ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®ã¹ãã©ã³èªå°äœã ïŒ é žã®ä»å ã«ããåŸãããå¡©ã®åœ¢ã«ããããšã
ç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²åèšããããã®é ã«èš
èŒã®ã¹ãã©ã³èªå°äœã ïŒ äžè¬åŒ ããã®åŒã§ããšïœã¯äžè¬åŒïŒïŒã®äžãšåãæ
矩ãæã€ãã ãæã€Î²âããããã·é ¢é žãåŒ·é žã§åŠçãã次ã
ã§å æ°Žå解ããŠäžè¬åŒ ããã®åŒã§ããšïœã¯äžè¬åŒïŒïŒã§ç€ºãããå®
矩ã«åŸããã ãæã€Î³âã¹ãã©ã¯ãã³ã圢æãããçé žã¡ãã«
ãã°ãã·ãŠã ã§åŠçããŠçžåœããαâã«ã«ããã·
γâã¹ããã©ã¯ãã³ã圢æããããã³ãããåå¿
ã«åŸã€ãŠãã«ããªã³åã¯ãã©ãã«ã ã¢ã«ãããã®
ååšã®äžã«è©²Î±âã«ã«ããã·âγâã¹ããã©ã¯ã
ã³ã«äžè¬åŒ HNR1R2 ïŒãã®åŒã§R1ããã³R2ã¯äžè¬åŒïŒïŒã®äžãšå
ãæå³ãæã€ãïŒã§è¡šããããèèªæã¢ãã³ãå
å¿ãããããšãç¹åŸŽãšããäžè¬åŒ ããã®åŒäžãã¯æ°ŽçŽ åååã¯ããã²ã³ååãæ
ãã¯ã¢ã«ãã«åºã§ããïŒR1ãšR2ã¯åäžåã¯ç°ãª
ããã®ã§ãã€ãŠãããããæ°ŽçŽ åååã¯ã¢ã«ãã«
åºãè¡šãããæãã¯R1ãšR2ãäžã€ã«ãªã€ãŠå«çª
çŽ è¢«çŽ ç°ã圢æãïŒïŒ¡ã¯COåºãè¡šããïŒïœã¯
ïŒåã¯ïŒã§ãããã ã§è¡šããããã¹ãã©ã³èªå°äœã®è£œæ³ã ïŒ äžè¬åŒ ããã®åŒã§ããšïœã¯äžè¬åŒïŒïŒã®äžãšåãæ
矩ãæã€ãã ãæã€Î²âããããã·é ¢é žãåŒ·é žã§åŠçãã次ã
ã§å æ°Žå解ããŠäžè¬åŒ ããã®åŒã§ããšïœã¯äžè¬åŒïŒïŒã§ç€ºãããå®
矩ã«åŸããã ãæã€Î³âã¹ãã©ã¯ãã³ã圢æãããçé žã¡ãã«
ãã°ãã·ãŠã ã§åŠçããŠçžåœããαâã«ã«ããã·
γâã¹ããã©ã¯ãã³ã圢æããããã³ãããåå¿
ã«åŸã€ãŠãã«ããªã³åã¯ãã©ãã«ã ã¢ã«ãããã®
ååšã®äžã«è©²Î±âã«ã«ããã·âγâã¹ããã©ã¯ã
ã³ã«äžè¬åŒ HNR1R2 ïŒãã®åŒã§R1ããã³R2ã¯äžè¬åŒïŒïŒã®äžãšå
ãæå³ãæã€ãïŒã§è¡šããããèèªæã¢ãã³ãå
å¿ãããæ°ŽçŽ åãªããŠã ã¢ã«ãããŠã ã«ããã©ã¯
ãã³ç°ãéå çã«éç°ããã次ãã§ååå è±æ°Žã«
ããç°åããããšãç¹åŸŽãšããäžè¬åŒ ããã®åŒäžãã¯æ°ŽçŽ åååã¯ããã²ã³ååãæ
ãã¯ã¢ã«ãã«åºã§ããïŒR1ãšR2ã¯åäžåã¯ç°ãª
ããã®ã§ãã€ãŠãããããæ°ŽçŽ åååã¯ã¢ã«ãã«
åºãè¡šãããæãã¯R1ãšR2ãäžã€ã«ãªã€ãŠå«çª
çŽ è¢«çŽ ç°ã圢æãïŒïŒ¡ã¯CH2åºãè¡šããïŒïœã¯
ïŒåã¯ïŒã§ãããã ã§è¡šããããã¹ãã©ã³èªå°äœã®è£œæ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7925041A FR2467202A1 (fr) | 1979-10-09 | 1979-10-09 | Nouveaux derives spiranniques, procede pour leur preparation, et medicaments les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5663980A JPS5663980A (en) | 1981-05-30 |
| JPH0153275B2 true JPH0153275B2 (ja) | 1989-11-13 |
Family
ID=9230467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13884880A Granted JPS5663980A (en) | 1979-10-09 | 1980-10-06 | Spirane derivative* its manufacture and drug composition containing it |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US4371538A (ja) |
| EP (1) | EP0027759B1 (ja) |
| JP (1) | JPS5663980A (ja) |
| AT (1) | ATE4981T1 (ja) |
| DE (1) | DE3065305D1 (ja) |
| FR (1) | FR2467202A1 (ja) |
| GR (1) | GR70255B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3730499A1 (de) * | 1987-02-10 | 1988-08-18 | Bayer Ag | Aminomethyltetrahydrofurane |
| GR990100386A (el) * | 1999-11-05 | 2001-07-31 | Πή β (ΌοΜο- ή Ύι-Î±Î»ÎºÏ Î»Î±ÎŒÎ¹ÎœÎ¿ÎŒÎµÎžÏ Î»)-γ-Î²Î¿Ï ÏÏ ÏολακÏÎ¿ÎœÎµÏ ÎºÎ±Î¹ Ïα αΜÏιÏÏοιÏα ÏÎ¿Ï Ï ÏεÏÏÎ±Ï ÎŽÏοÏÎ¿Ï ÏαΜικα αΜαλογα ÏαΜ Μεα ÏÏÏÏοÏÏ Ïα ΜοοÏÏοÏα, αΜÏι-αΜοικα (αÏΞεΜεια ÏÎ¿Ï alzheimer), αΜÏιεÏιληÏÏικα και ÎœÎµÏ ÏοÏÏοÏÏαÏÎµÏ Ïικα ÏαÏΌακα Όε ΌοΜαΎικο, καÏα Ïο ΌεÏÏι ÏÎ¿Ï ÎŽÎµ ..... | |
| JP4433311B2 (ja) | 2005-09-12 | 2010-03-17 | ãœããŒæ ªåŒäŒç€Ÿ | åå°äœèšæ¶è£ 眮ãé»åæ©åšåã³ã¢ãŒãèšå®æ¹æ³ |
| WO2013172239A1 (ja) * | 2012-05-17 | 2013-11-21 | Jsræ ªåŒäŒç€Ÿ | é žæ¡æ£å¶åŸ¡å€ãææŸå°ç·æ§æš¹èçµæç©ãã¬ãžã¹ããã¿ãŒã³åœ¢ææ¹æ³ãååç©åã³ååç©ã®è£œé æ¹æ³ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA631328A (en) * | 1961-11-21 | F. Parcell Robert | 2(1-(1-amino) cyclohexyl) thiophene derivatives and method of preparation thereof | |
| US2490937A (en) * | 1945-08-17 | 1949-12-13 | Abbott Lab | Aminoalkyl-phenyl lactones |
| US2960441A (en) * | 1957-09-17 | 1960-11-15 | Warner Lambert Pharmaceutical | Therapeutic compositions of salts of 3, 3-pentamethylene-4-hydroxybutyric acid |
| JPS5928557B2 (ja) * | 1974-04-18 | 1984-07-13 | 倧æ£è£œè¬æ ªåŒäŒç€Ÿ | æ°èŠã¹ããååç©ã®è£œæ³ |
-
1979
- 1979-10-09 FR FR7925041A patent/FR2467202A1/fr active Granted
-
1980
- 1980-09-17 GR GR62904A patent/GR70255B/el unknown
- 1980-10-06 JP JP13884880A patent/JPS5663980A/ja active Granted
- 1980-10-08 DE DE8080401437T patent/DE3065305D1/de not_active Expired
- 1980-10-08 AT AT80401437T patent/ATE4981T1/de active
- 1980-10-08 EP EP80401437A patent/EP0027759B1/fr not_active Expired
- 1980-10-09 US US06/195,692 patent/US4371538A/en not_active Expired - Lifetime
-
1981
- 1981-10-23 US US06/314,339 patent/US4377689A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0027759B1 (fr) | 1983-10-12 |
| EP0027759A1 (fr) | 1981-04-29 |
| JPS5663980A (en) | 1981-05-30 |
| US4371538A (en) | 1983-02-01 |
| FR2467202B1 (ja) | 1982-11-05 |
| ATE4981T1 (de) | 1983-10-15 |
| US4377689A (en) | 1983-03-22 |
| GR70255B (ja) | 1982-09-02 |
| DE3065305D1 (en) | 1983-11-17 |
| FR2467202A1 (fr) | 1981-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3420851A (en) | Novel dibenzoxepines | |
| JPS6129950B2 (ja) | ||
| JPH10510554A (ja) | 眮æããããã³ãžã«ã¢ãããããªãžã³ååç© | |
| KR101650776B1 (ko) | 벀조ëì¥ì ì ë첎 ë° ìŽì ì ì¡°ë°©ë²ê³Œ ì©ë | |
| EP2880023A1 (fr) | Derives de griseofulvine | |
| DE2839279A1 (de) | Derivate des 1,2,3,3a,8,8a-hexahydropyrrolo eckige klammer auf 2,3-b eckige klammer zu indols, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
| JPH0153275B2 (ja) | ||
| US4778812A (en) | 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof | |
| DE3320102C2 (ja) | ||
| JPH0378858B2 (ja) | ||
| US4837240A (en) | Aminoalkyl secocanthine derivatives and their use | |
| DD299425A5 (de) | Neue 4,4-disubstituierte piperidin-derivate und verfahren zu ihrer herstellung | |
| EP0116347A1 (en) | Substituted 1-azaspiro(4.5)decanes and 1-azaspiro(5.5)-undecanes, intermediates and a process for their preparation, and their use as medicaments | |
| JPH0319236B2 (ja) | ||
| US4835271A (en) | Aminoalkyl secocanthine derivatives and their use | |
| HU196797B (en) | Process for producing 5-substituted oktahydro-indoline derivatives | |
| DE69007904T2 (de) | 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus. | |
| JPH0352465B2 (ja) | ||
| GB2030133A (en) | Tetrahydrothiopyrano (2,3-b) indole derivatives | |
| US3960872A (en) | 1 Alkyl-4-(10:oxo or hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidine compounds | |
| US3209007A (en) | (dibenzo (a, d) 1, 4-cycloheptene-5-yloxy) amines | |
| DE69127549T2 (de) | 5h-dibenzo[a,d]cycloheptene als muscarinic-rezeptor-antagonist | |
| US3968115A (en) | 1-Alkyl-4-(10 and/or 11)-bromo-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-ylidene piperidine compounds | |
| US3687937A (en) | 1,5-methano-3-benzazocine derivatives | |
| EP0573548B1 (en) | Neuroprotectant agents |